{'fraction_non_alphanumeric': 0.048599670510708404, 'fraction_numerical': 0.042833607907743, 'mean_word_length': 4.625, 'pattern_counts': {'":': 0, '<': 5, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding.

OBJECTIVE
This study aimed to explore the efficacy of octreotide acetate combined with somatostatin (OA + SS) for the treatment of patients with cirrhosis and upper gastrointestinal bleeding (UGIB).


METHODS
A total of 118 patients with cirrhosis and UGIB in our hospital were enrolled from June 2018 to September 2019. Fifty-seven were treated with OA alone (Group A) whereas 61 were treated with OA + SS (Group B).


RESULTS
The therapeutic effects, inflammatory cytokines, liver function indices, and relative expression levels of miR-1291 and miR-331-3p were then observed. Compared with the patients in Group A, those in Group B had lower post-treatment inflammatory cytokine levels (P < 0.05), better post-treatment liver function indices (P < 0.05), lower incidences of adverse reactions (P < 0.05), and a higher total effective rate (P < 0.05). The OA + SS treatment group had upregulated miR-1291 and downregulated miR-331-3p (P < 0.05).


CONCLUSION
OA + SS therapy is safe and effective for the treatment of patients with cirrhosis and UGIB.